Friday, April 09, 2021 8:15:53 AM
I’m glad I’m not the only who noticed this.
This Grizz Adam’s guy on YAhoo message boards made big on SAVA and called it at 3. He also called GLSI and said CYDY and this will be next.
Now he’s calling this. So here I am.
Long !
This Grizz Adam’s guy on YAhoo message boards made big on SAVA and called it at 3. He also called GLSI and said CYDY and this will be next.
Now he’s calling this. So here I am.
Long !
Recent BCTX News
- BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer • GlobeNewswire Inc. • 05/26/2026 11:30:00 AM
- BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 • GlobeNewswire Inc. • 05/22/2026 11:30:00 AM
- BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™ • GlobeNewswire Inc. • 05/15/2026 11:30:00 AM
- BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer • GlobeNewswire Inc. • 05/14/2026 11:30:00 AM
- BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study • GlobeNewswire Inc. • 05/13/2026 11:30:00 AM
- BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients • GlobeNewswire Inc. • 05/12/2026 11:30:00 AM
- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer • GlobeNewswire Inc. • 05/06/2026 11:30:00 AM
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026 • GlobeNewswire Inc. • 04/27/2026 11:30:00 AM
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models • GlobeNewswire Inc. • 04/21/2026 11:30:00 AM
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting • GlobeNewswire Inc. • 04/20/2026 11:30:00 AM
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License • GlobeNewswire Inc. • 03/31/2026 08:05:06 PM
- BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference • GlobeNewswire Inc. • 03/18/2026 11:30:00 AM
- BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting • GlobeNewswire Inc. • 03/10/2026 11:30:00 AM
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting • GlobeNewswire Inc. • 03/05/2026 09:04:34 PM
- BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License • GlobeNewswire Inc. • 02/18/2026 10:30:00 PM
- BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation • GlobeNewswire Inc. • 01/28/2026 12:30:00 PM
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering • GlobeNewswire Inc. • 01/15/2026 09:05:00 PM
- BriaCell Therapeutics Shares Sink After $30 Million Capital Raise • IH Market News • 01/14/2026 03:18:54 PM
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering • GlobeNewswire Inc. • 01/14/2026 02:00:22 AM
- BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- How $594B in Precision Tech is Cracking the Metastatic Cancer Code • PR Newswire (Canada) • 01/07/2026 03:32:00 PM
- How $594B in Precision Tech is Cracking the Metastatic Cancer Code • PR Newswire (US) • 01/07/2026 03:32:00 PM
